Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04291417 · ClinicalTrials.gov registry record
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W
A clinical trial, sponsored by Beckman Coulter.
- Completed
- Registry status
- 1,700
- Enrollment target
NCT04291417: Completed study, sponsored by Beckman Coulter.
NCT04291417 is a clinical trial that has completed, run by Beckman Coulter. The registered enrollment target is 1,700 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04291417 has completed, sponsored by Beckman Coulter.
- COMPLETED
- Registry status
- 1,700 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentation for sepsis patients (simulated primary endpoint), with concomitant reductions in length of stay and in-hospital mortality for those patients (secondary endpoints).
Primary Outcome
Validate MDW's ability to reduce time to first antibiotics ordered by physician (decision to treat)-Simulated
Interventions
- DIAGNOSTIC_TEST CBC-DIFF Monocyte Volume Width Distribution (MDW)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2019-11-20 |
| Est. Completion | 2020-06-17 |
What the finished NCT04291417 record still lists
NCT04291417 is an observational study that tracks outcomes without assigning an intervention. Its 1,700 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which CBC-DIFF Monocyte Volume Width Distribution (MDW) is the first listed.
NCT04291417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04291417 about?
NCT04291417 is a clinical study titled "Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W". The purpose of this study is to demonstrate that addition of the Monocyte Width Distribution (MDW) parameter to current standard of care improves a clinician's ability to recognize sepsis in the Emergency Department, resulting in earlier decision to administer antibiotics from time of ED presentatio...
What is the current status of trial NCT04291417?
This trial is currently completed. The enrollment target is 1,700 participants. The study started on 2019-11-20. Estimated completion is 2020-06-17.
What interventions are being tested in trial NCT04291417?
The interventions under investigation include: CBC-DIFF Monocyte Volume Width Distribution (MDW) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04291417?
This trial is sponsored by Beckman Coulter, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04321200 · 1,700 participants
PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
- NCT06238622 · 1,700 participants · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- NCT07284901 · 1,700 participants · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- NCT07304531 · 1,705 participants
First To Know Pregnancy Test - Clinical Evaluation Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI